Follow-up after returning home from T-cell lymphoma treatment: coordinating tests, medicines and new symptoms

Some patients return home in complete remission, others continue an oral medicine, and others have recently left a transplant unit. Those situations have different follow-up tasks. The discharge summary should state the current disease status, date of the latest assessment and whether the next stage is observation, continuing therapy or further investigation. A general statement that the patient is stable may leave the receiving clinician unsure what to do next.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The 2025 ESMO–EHA guideline does not recommend routine PET-CT or diagnostic CT surveillance for PTCL patients in complete remission. Clinical history and examination still matter, and investigations should reflect the entity, previous therapy and particular findings. Not scheduling regular PET does not mean that recurrence is being ignored. New symptoms or concerns may still justify imaging for a defined clinical question. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025
For mycosis fungoides or Sézary syndrome, follow-up may integrate skin, blood, lymph nodes and other affected sites. NCI discusses these diseases with a separate staging and treatment framework. A general nodal-PTCL imaging schedule therefore cannot replace dermatologic review. Transfer previous skin-extent assessments, pathology, blood findings and response information so the local team can compare the relevant disease compartments. NCI PDQ: Mycosis Fungoides and Sézary Syndrome Treatment
When tests are done in a different hospital, arrange delivery of the full result rather than a verbal description that it was normal. Include the collection date, reference range and reason the investigation was requested. The clinician reviewing a trend needs to know whether the sample was taken during infection, after a medicine change or at another meaningful point in the course.

Quick answer

Full guide

Establish the treatment state at the point of return

Obtain a follow-up plan and identify the clinician or department able to receive the patient locally. NCI's survivorship information emphasizes a treatment summary and care plan. These can allocate lymphoma monitoring, treatment-related problems and general health care to appropriate services. In cross-border care, clarify who interprets and implements the original hospital's recommendations so neither team assumes the other has arranged the next test. NCI: Follow-Up Medical Care after Cancer Treatment

Complete-remission follow-up is not repeated routine PET

The 2025 ESMO–EHA guideline does not recommend routine PET-CT or diagnostic CT surveillance for PTCL patients in complete remission. Clinical history and examination still matter, and investigations should reflect the entity, previous therapy and particular findings. Not scheduling regular PET does not mean that recurrence is being ignored. New symptoms or concerns may still justify imaging for a defined clinical question. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Ask about the planned visit frequency, the content of each assessment and circumstances that should trigger earlier contact. A commercial screening package is not a substitute for the specialist plan, and arranging frequent scans at several hospitals because of anxiety can complicate care. Patients with residual disease, ongoing treatment or transplant-specific requirements may need a different approach. The conditions attached to a recommendation should remain clear.

Preserve the end-of-treatment comparison point

The latest response assessment provides an important reference for later changes. Retain its report and original images with the interval from the final treatment administration. Lugano classification provides a framework for describing response; residual anatomy and metabolic activity require appropriate interpretation. The size of a remaining mass in one report may not by itself establish active lymphoma. Cheson et al.: Lugano classification for lymphoma evaluation and response

If an uncertain lesion remains, the handover should record why repeat imaging, observation or biopsy was proposed. Do not simply tell the local doctor that everything has resolved, or assume that a residual shadow proves treatment failure. Comparison needs the original sites, treatment course and current symptoms. The original team may help interpret an unresolved finding when the receiving clinician has the relevant records.

Report meaningful changes before the next scheduled visit

Persistent or enlarging lumps, unexplained fever, substantial night sweats, weight loss, worsening itch or new sustained local pain should be described to the follow-up clinician. They can reflect lymphoma, infection or other conditions. Record onset, progression and associated symptoms instead of waiting until the appointment to give a general account of feeling unwell. A scheduled review date is not a reason to postpone reporting a change that is getting worse.

Suspected recurrence may require new imaging or tissue. ESMO–EHA recommends rebiopsy at relapse or progression because similar findings may have other explanations. CAP's specimen principles reinforce the need to plan sampling around the required studies. Bring earlier pathology for comparison. A history of PTCL does not automatically establish that every new lesion is the same disease. CAP/ASCP: Laboratory Workup of Lymphoma in Adults guideline d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Keep an urgent local route for fever and infection

Recent treatment, incomplete blood-count recovery and continuing immunosuppression can sustain infection risk after travel ends. Follow the team's fever threshold, and seek immediate care for concerning features such as shaking chills, breathing difficulty or altered awareness. NCI's infection and neutropenia information emphasizes timely action. Sending a message abroad and waiting for a reply is not an adequate emergency pathway. NCI: Infection and Neutropenia during Cancer Treatment

Keep recent medicines, last administration date, transplant information and antimicrobial allergies readily available. Relatives should know which emergency service can assess the patient overnight and where blood testing and relevant support are available. Advice across time zones can contribute to later decisions, but an acute deterioration requires professionals able to examine and treat the patient in person.

Assign responsibility for continuing prescriptions and results

If anticancer or preventive medicines continue, confirm the local prescribing route, supply, monitoring tests and result reviewer before leaving. Indications, formulations and availability may differ between China and the country of residence. A Chinese prescription is not a guarantee of direct use in every country. China's national guidance can help clinicians identify the disease and treatment-setting basis of the original plan. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

The receiving clinician and original service should agree on stopping preventive medicines and handling abnormal blood counts or organ tests. Do not stretch a dwindling supply by taking alternate-day doses or buy a different drug in the same broad class without review. If monitoring or supply cannot be sustained, raise the problem early enough for the team to create an executable plan rather than waiting until treatment has already been interrupted.

Transplant follow-up needs additional detail

After allogeneic transplantation, immunosuppression, graft-versus-host disease and infection surveillance need a specialist pathway. Autologous recipients also require attention to recovery, blood counts and organ health. EBMT's chapter on early and long-term controls shows why the handover should identify visit frequency, medication review and circumstances requiring referral back. Occasional general checkups when the patient feels unwell do not replace this arrangement. Suárez-Lledó and Rovira: Follow-up after HCT, EBMT Handbook 2024

New diarrhea, skin changes, dry eyes or mouth, jaundice and respiratory symptoms after allogeneic transplantation may require assessment for several causes, including graft-versus-host disease. Patients should not independently increase or reduce corticosteroids or immunosuppressants. Prior mogamulizumab exposure should be known to both transplant and receiving teams, because its prescribing information warns of serious complications with subsequent allogeneic transplantation. DailyMed: POTELIGEO mogamulizumab prescribing information, February 2026

Cutaneous disease requires its own assessment pathway

For mycosis fungoides or Sézary syndrome, follow-up may integrate skin, blood, lymph nodes and other affected sites. NCI discusses these diseases with a separate staging and treatment framework. A general nodal-PTCL imaging schedule therefore cannot replace dermatologic review. Transfer previous skin-extent assessments, pathology, blood findings and response information so the local team can compare the relevant disease compartments. NCI PDQ: Mycosis Fungoides and Sézary Syndrome Treatment

With the clinician's agreement, photographs taken under similar lighting and at a similar distance may help show a visible change. They do not diagnose it. New eruptions can arise from lymphoma, drugs or infection and need local examination when appropriate. If skin-directed therapy is to continue, establish that the required equipment and personnel are available at home before relying on it in the discharge plan.

Address treatment effects alongside disease surveillance

Persistent numbness, poor balance, fatigue, altered sleep and reduced intake can interfere with recovery. NCI resources on nerve problems and fatigue describe their functional consequences and the need to consider treatable contributors. At visits, explain the effect on walking, bathing, employment and family responsibilities rather than reporting only whether a lump remains. NCI: Nerve Problems and Cancer Treatment NCI: Fatigue and Cancer

Particular chemotherapy, radiation or transplant exposures may warrant assessment of cardiac, endocrine, bone, oral or other longer-term health issues. The treatment summary should guide the clinician's selection of investigations. Patients do not need to purchase every test listed in a general survivorship checklist, but remission should not become a reason to overlook symptoms that continue to limit daily life.

Reassess vaccination and everyday infection precautions

Immunosuppression and transplantation can change vaccination needs, and some vaccines may need to be deferred or repeated. CDC's immunocompromised-traveler guidance emphasizes assessment using immune status and treatment history. Do not copy a healthy adult's travel or routine vaccination schedule without review. Give the clinician previous vaccination records and the current immunosuppressive list, and identify the service responsible for arranging the next steps. CDC Yellow Book 2026: Immunocompromised Travelers

Ask for practical advice on food hygiene, contact with groups and later journeys in the context of the patient's current condition. Measures should be sustainable and justified rather than creating indefinite isolation from family. If a household member becomes ill or a specific exposure occurs, contact the team for current advice. A general instruction given at discharge may not address a new situation months later.

Include fertility, emotional health and return to work

Treatment may affect reproductive health. The 2025 ASCO fertility-preservation guideline supports discussion within cancer care, and questions about present function and options may remain relevant after treatment. Whether and when pregnancy can be considered depends on disease status, actual treatment and medicines. Return of menstruation or subjective recovery alone does not settle those questions. ASCO: Fertility Preservation in People With Cancer, 2025 guideline update

Anxiety around assessments is common. If worry persistently disrupts sleep, eating or ordinary activities, seek psychological or mental-health support. NCI's information on cancer-related adjustment and distress helps identify when additional help may be useful. Relatives can accompany the patient and record questions without requiring constant optimism. Returning to employment and social activities may need gradual adjustment to the person's present capacity. NCI PDQ: Adjustment to Cancer, Anxiety and Distress, patient version

Update a short action list after each review

Record the current conclusion, medicines, next tests, responsible clinician and conditions for earlier contact. List pending results separately and confirm who will communicate them. If the local team changes treatment, preserve the reason and share the update with the original service. If the original team provides remote advice, a clinician able to prescribe and monitor locally should implement it, avoiding two conflicting medication plans being followed at once.

Visit frequency and emphasis may change as remission continues. Reduced lymphoma-specific surveillance does not mean that every long-term health task has ended. Ask which responsibilities can move to primary care and which remain with hematology or the transplant service. Clear allocation lets the patient resume ordinary life while retaining a dependable point of contact if circumstances change.

Close the loop on investigations performed elsewhere

When tests are done in a different hospital, arrange delivery of the full result rather than a verbal description that it was normal. Include the collection date, reference range and reason the investigation was requested. The clinician reviewing a trend needs to know whether the sample was taken during infection, after a medicine change or at another meaningful point in the course.

Keep the patient's copy of the plan current and remove superseded instructions from the active medication folder. A relative can assist with organization, but the patient should understand the next appointment and how to seek help. Reliable follow-up is built from completed reviews and communicated results, not simply from having a calendar full of tests.